Know Cancer

forgot password

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Phase 1
3 Years
21 Years
Open (Enrolling)
Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma

Thank you

Trial Information

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features



- To estimate the maximum-tolerated dose and/or recommended phase II dose of Seneca
Valley virus-001 (NTX-010) when administered as a single infusion to pediatric patients
with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with
neuroendocrine features (Wilms tumor, retinoblastoma, adrenocortical carcinoma, or
carcinoid tumors). (Part A [completed])

- To confirm that there is viral replication in these patients following NTX-010
administration. (Part A [completed])

- To define and describe the toxicities of NTX-010 when administered on this schedule.
(Part A [completed])

- To determine whether the number of regulatory T cells (as measured by flow cytometry)
can effectively be reduced following administration of NTX-010 plus low-dose metronomic
and intravenous cyclophosphamide. (Part B)

- To characterize the pharmacokinetics (time course of viral clearance) following NTX-010
administration in these patients.


- To preliminarily define the antitumor activity of NTX-010 within the confines of a
phase I study. (Part A [completed])

- To evaluate the development of neutralizing antibodies to NTX-010 following IV
administration of NTX-010. (Part A [completed])

- To evaluate development of neutralizing antibodies to NTX-010 following the combination
of NTX-010 and cyclophosphamide. (Part B)

- To investigate the presence and permissivity of occult circulating tumor cells prior to
and after the initial intravenous administration of NTX-010.

OUTLINE: This is a multicenter study.

Part A (completed): Patients receive Seneca Valley virus-001 (NTX-010) IV over 1 hour on day

Part B: Patients receive cyclophosphamide IV orally (PO) on days 1-14 and NTX-010 IV over 1
hour on day 8. In the absence of disease progression or unacceptable toxicity, patients then
receive cyclophosphamide orally (PO) on days 22-35, plus cyclophosphamide IV over 1 hour and
NTX-010 IV over 1 hour on day 29.

Tumor tissue samples are collected at baseline for biomarker studies. Blood and stool
samples are collected periodically for neutralizing antibody and viral clearance studies.
Additional blood samples may also be collected for the presence and permissivity of occult
tumor cells.

After completion of study treatment, patients are followed up periodically for up to 1 year.

Inclusion Criteria


- Histologically confirmed diagnosis of 1 of the following:

- Neuroblastoma

- Rhabdomyosarcoma

- Wilms tumor

- Retinoblastoma

- Adrenocortical carcinoma

- Carcinoid tumor

- Relapsed or refractory disease

- Measurable or evaluable disease

- No known curative therapy or therapy proven to prolong survival with an acceptable
quality of life

- No known pulmonary tumors or metastases > 5 cm, as evaluated by chest CT scan

- No clinically significant pulmonary and/or pericardial effusions (≥ grade 3), as
evaluated by ECHO

- No primary CNS tumors or known metastatic CNS disease involvement


- Karnofsky performance status (PS) 50-100% (for patients > 16 years of age)

- Lansky PS 50-100% (for patients ≤ 16 years of age)

- Peripheral ANC ≥ 1,000/mm^3

- Platelet count ≥ 100,000/mm^3 (transfusion independent, defined as no platelet
transfusions within a 7-day period before study enrollment)

- Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)

- Creatine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on
age/gender as follows:

- ≤ 0.8 mg/dL (for patients 3 to 5 years of age)

- ≤ 1.0 mg/dL (for patients 6 to 9 years of age)

- ≤ 1.2 mg/dL (for patients 10 to 12 years of age)

- ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)

- ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)

- ≤ 1.7 mg/dL (for male patients ≥ 16 years of age)

- Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times upper limit of normal

- SGPT ≤ 110 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)

- Serum albumin ≥ 2 g/dL

- Oxygen saturation > 92% on room air

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to comply with the safety monitoring requirements of the study, in the opinion
of the investigator

- Completely toilet trained

- No chronic diarrhea or urinary incontinence during the day or night, , and no
in-dwellling urinary catheters

- No uncontrolled infection

- No known pregnant member of the household


- Fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy

- At least 6 months since prior total-body irradiation (TBI), craniospinal
radiotherapy, or radiotherapy to ≥ 50% of the pelvis

- At least 3 months since prior stem cell transplantation or rescue (without TBI)

- No evidence of active graft-vs-host disease

- At least 6 weeks since other prior substantial bone marrow radiotherapy or treatment
with therapeutic doses of MIBG

- More than 3 weeks since prior myelosuppressive chemotherapy

- At least 2 weeks since prior local palliative radiotherapy (small port)

- More than 7 days since prior growth factor(s) that support platelet or white blood
cell number or function

- At least 7 days since prior biologic agents

- At least 3 half-lives since prior monoclonal antibodies

- More than 7 days since prior viral immunizations, including influenza

- At least 42 days since the completion of any type of immunotherapy, e.g., tumor

- No other viral immunizations after enrolling on study until 28 days after their last
planned Seneca Valley virus-001 infusion or until documented viral clearance,
whichever is longest

- Concurrent corticosteroids allowed provided the patient has been on a stable or
decreasing dose for the past 7 days

- No other concurrent investigational drugs

- No other concurrent anticancer agents (e.g., chemotherapy, radiotherapy,
immunotherapy, or biologic therapy)

- Prior treatment with Seneca Valley virus-001 is not allowed

Type of Study:


Study Design:

Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability

Safety Issue:


Principal Investigator

Michael J. Burke, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Masonic Cancer Center, University of Minnesota



Study ID:




Start Date:

September 2009

Completion Date:

Related Keywords:

  • Adrenocortical Carcinoma
  • Gastrointestinal Carcinoid Tumor
  • Kidney Cancer
  • Neuroblastoma
  • Retinoblastoma
  • Sarcoma
  • recurrent neuroblastoma
  • previously treated childhood rhabdomyosarcoma
  • recurrent childhood rhabdomyosarcoma
  • recurrent Wilms tumor and other childhood kidney tumors
  • recurrent retinoblastoma
  • recurrent adrenocortical carcinoma
  • recurrent gastrointestinal carcinoid tumor
  • Carcinoid Tumor
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Neuroblastoma
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Adrenocortical Carcinoma
  • Malignant Carcinoid Syndrome
  • Gastrointestinal Neoplasms
  • Sarcoma



Children's Hospital of Orange County Orange, California  92668
Children's National Medical Center Washington, District of Columbia  20010-2970
Children's Hospital and Regional Medical Center - Seattle Seattle, Washington  98105
Children's Memorial Hospital - Chicago Chicago, Illinois  60614
St. Jude Children's Research Hospital Memphis, Tennessee  38105-2794
Midwest Children's Cancer Center at Children's Hospital of Wisconsin Milwaukee, Wisconsin  53226
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio  45229-3039
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas  75390
Baylor University Medical Center - Houston Houston, Texas  77030-2399
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California  94115
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston, Massachusetts  02115
C.S. Mott Children's Hospital at University of Michigan Medical Center Ann Arbor, Michigan  48109-0286
Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota  55455
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis St. Louis, Missouri  63110
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center New York, New York  10032
Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania  15213
Riley's Children Cancer Center at Riley Hospital for Children Indianapolis, Indiana  46202-5225
UAB Comprehensive Cancer Center Birmingham, Alabama  35294